Total Funding
59
45
Total FundingGrant raised
Growth Score
-17 pts
Heat Score
-20 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
100535
Oryzon Genomics is a biopharmaceutical company developing epigenetics-based therapeutics for patients with cancer and CNS disorders.
- Tamara Maes: President of the Scientific Advisory Board of Oryzon GenomicsPast Role: Oryzon Genomics SA, CSO Oryzon Genomics
- Sonia Gutiérrez: Chief of Clinical Operations
About the Company
Oryzon Genomics is a biopharmaceutical company developing epigenetics-based therapeutics for patients with cancer and CNS disorders. Oryzon is able to identify and validate biomarkers and therapeutic targets through its epigenetic platform and turn them into advanced and personalized therapies.
Oryzon Genomics has a growing portfolio, with two
compounds in Phase II clinical trials: iadademstat (aka ORY-1001), a potent and selective LSD1 inhibitor for oncology, and vafidemstat (aka ORY-2001), a CNS optimized LSD1 inhibitor for the treatment of neurological diseases. The portfolio includes ORY-3001, a selective LSD1 inhibitor in preclinical development for the treatment of non-oncological diseases.
